Hepatocellular carcinoma (HCC) is the most common primary liver tumor and the third cause of cancer-related deaths worldwide. HCC is the consequence of malignant transformation of hepatocytes and mainly occurs in patients with cirrhosis. Hepatitis C virus (HCV) chronic infection is a leading cause of end-stage liver disease and HCC in the Western countries [1]. The approval of direct-acting antiviral agents (DAAs) for the treatment of HCV has revolutionized the management of the disease, as no absolute contraindication to treatment exists and sustained virological response rates (SVR) exceeding 90% can be achieved independently of disease severity [2].